Long-term Follow-up of Huntington's Disease Patients Treated With Intrastriatal Fetal Neuron Allograft

简要总结

详细描述

主要结局

次要结局

• Events and adverse reactions recording since the transplantation(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Slopes comparison of neurological scores (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) before and after transplantation(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Comparison of the clinical evolution (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) of transplanted patients with that of non-transplanted patients in the BioHD cohort(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Slopes comparison of cognitive scores (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) before and after transplantation(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Slopes comparison of neuropsychologic scores (Mattis Dementia Rating Scale/Trail Making test/Hopkins Verbal Learning Test/Categorical fluency/Sign barrier test/Montgomery-Åsberg Depression Rating Scale (MADRS)) before and after transplantation(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Correlation between graft activity measured by imaging and patient performance(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Correlation between post-mortem brain observations and patient performance before death(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Research into predictive factors (relationships between fetal haplotypes, patient haplotypes and appearance of alloimmunization phenomena) of the evolution of transplanted patients(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Research and identification of anti-MHC Ab from samples acquired under the MIG-HD and Post-MIGHD protocols as well as in care(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Correlation between post-mortem observations of the brains of deceased patients and measurements obtained by MRI and PET-SCAN in studies MIG-HD and BioHD(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Slopes comparison of psychiatric scores (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) before and after transplantation(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)
• Analysis of brains collected as part of MIG-HD and POST-MIGHD i) to quantify neuropathological lesions ii) to search for markers of inflammatory reactions(From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed)